Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
Eligible age
6+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and pediatric participants with atopic dermatitis. The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which includes an initial two-week period of co-treatment with topical corticosteroids (TCS). The primary efficacy objective of this study is to assess the ability of ShA9, compared to placebo (vehicle), to prolong the period of atopic dermatitis control over 12 weeks after conclusion of an initial two-week period of co-treatment with TCS.
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
You may qualify if…
- ✓ Each individual must meet all of the following criteria at Screening to be eligible for enrollment as a study participant:
- ✓ 1. Participant and/or parent/legal guardian must be able to understand and provide informed consent and assent (if applicable).
- ✓ 2. Male or female participant 6 years of age or older.
- ✓ 3. Meet ADRN Standard Diagnostic Criteria for active AD.
- ✓ Each individual must meet all of the following criteria at Baseline to be eligible for enrollment as a study participant:
- ✓ 4. Have at least 7 cm2 of lesional skin within the upper extremities, lower extremities, and/or trunk. Lesions on the face, neck, hands, feet, and intertriginous areas do not count toward the required area, as samples may not be taken from these areas. The required area may be one contiguous area or may be comprised of multiple areas with a compliant total area.
- ✓ 5. Have at least 3% body surface area of AD involvement as indicated by derived total area of involvement score during SCORAD assessment.
- ✓ 6. Have an IGA score of two or greater.
You may not qualify if…
- ✕ Individuals who meet any of the following criteria at Screening or Baseline are not eligible for enrollment as study participants:
- ✕ 1. Inability or unwillingness to give written informed consent or comply with study protocol.
- ✕ 2. Has self-reported as pregnant or lactating during the Screening or Baseline Visit, or is pregnant as indicated by a positive pregnancy test result obtained at the Screening or Baseline Visit.
- ✕ 3. Sensitivity to or difficulty tolerating Dove® fragrance-free bar soap, Cetaphil® lotion, alcohol-based cleaners, clobetasol and fluocinonide ointments, triamcinolone ointment, hydrocortisone ointment, glycerol, hydroxyethylcellulose or soy products.
- ✕ 4. Known recalcitrance to topical steroids, including class 1 steroids, within 6 months of the Screening Visit.
- ✕ 5. History of serious life-threatening reaction to tape or adhesives.
- ✕ 6. Known allergy to all antibiotics to which S. hominis A9 is sensitive. These include ampicillin-sulbactam, cefazolin, cefoxitin, clindamycin, daptomycin, doxycycline, levofloxacin, linezolid, minocycline, moxifloxacin, mupirocin, nitrofurantoin, oxacillin, rifampin, trimethoprim-sulfamethoxazole, and vancomycin.
- ✕ 7. Has a major defect in the epidermal barrier such as open wounds or genodermatoses (e.g., Netherton's syndrome).
Where it's recruiting
Source: ClinicalTrials.gov · NCT06504160 · last updated 2026-06-02